82 related articles for article (PubMed ID: 17386127)
1. TEACH: Tykerb evaluation after chemotherapy.
Moy B; Goss PE
Clin Breast Cancer; 2007 Feb; 7(6):489-92. PubMed ID: 17386127
[No Abstract] [Full Text] [Related]
2. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
3. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
5. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Pikó B;
Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
[No Abstract] [Full Text] [Related]
6. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Lo YH; Ho PC; Zhao H; Wang SC
Anticancer Res; 2011 Mar; 31(3):789-95. PubMed ID: 21498698
[TBL] [Abstract][Full Text] [Related]
7. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
8. [Advances in research on treatment of breast cancer with lapatinib].
Ma CD; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
[No Abstract] [Full Text] [Related]
9. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
Ito Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
[No Abstract] [Full Text] [Related]
10. Reply to F. Ades.
Guan Z
J Clin Oncol; 2013 Nov; 31(33):4272. PubMed ID: 24127453
[No Abstract] [Full Text] [Related]
11. Neratinib (HKI-272) in the treatment of breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
[TBL] [Abstract][Full Text] [Related]
12. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
Montemurro F; Aglietta M
Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
[TBL] [Abstract][Full Text] [Related]
15. Herceptin in early breast cancer: a call for judicious use.
Thorat MA
Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
[No Abstract] [Full Text] [Related]
16. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
18. Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
Ades F
J Clin Oncol; 2013 Nov; 31(33):4271. PubMed ID: 24127451
[No Abstract] [Full Text] [Related]
19. Lessons from breast cancer trials of HER2-kinase inhibitors.
Krop IE
Lancet Oncol; 2016 Mar; 17(3):267-268. PubMed ID: 26822399
[No Abstract] [Full Text] [Related]
20. Targeted therapies: HER2-positive breast cancer-sifting through many good options.
Krop IE
Nat Rev Clin Oncol; 2013 Jun; 10(6):312-3. PubMed ID: 23629473
[No Abstract] [Full Text] [Related]
[Next] [New Search]